Abstract Details

Title Patient Experience With Once-daily Deutetrabenazine Extended-release Tablets for the Treatment of Tardive Dyskinesia in Individuals With Prior Valbenazine Use

Topic Movement Disorders

Presentation(s) P7 - Poster Session 7 (8:00 AM-9:00 AM)

Poster/Presentation
Number 16-003

Objective To explore patient-reported experiences with once-daily (QD) deutetrabenazine extended-release tablets among those with prior valbenazine use (PVU).

Background Deutetrabenazine is used for treatment of tardive dyskinesia (TD) and Huntington disease (HD)–related chorea and can be administered QD or twice daily (BID). A survey study explored patient-reported experience with QD deutetrabenazine extended-release tablets. This subgroup analysis explored responses from participants taking deutetrabenazine QD for their TD who reported PVU.

Design/Methods

This noninterventional, prospective, cross-sectional, IRB-approved survey included adults with TD/HD-related chorea taking deutetrabenazine QD. Participants in the Teva Shared Solutions patient support program who completed/were due for their 12-week nurse outreach phone call were eligible. Only TD results are reported in this analysis.

Results 209 participants with TD completed the survey, with 54 participants reporting PVU (mean age 56.7 years, 78% female, 91% White) and 100 participants reporting no prior TD medication (de novo; 61.7 years, 70% female, 97% White). ≥82% of participants in both groups liked that their doctor could adjust their dose. >94% of participants in both groups reported that their extra movements were very much/much/minimally improved with deutetrabenazine QD. In both groups, >77% strongly agreed/agreed that since starting deutetrabenazine QD, reduction in their extra movements had improved their comfort in social settings and emotional well-being. Most participants reported it was very/somewhat easy to take deutetrabenazine QD (PVU: 96%; de novo: 99%) and 96% across groups strongly agreed/agreed that they will continue taking deutetrabenazine QD. 91% (PVU) and 89% (de novo) reported satisfaction with deutetrabenazine QD.

Conclusions Most participants with TD who reported previously using valbenazine and those who initiated deutetrabenazine QD de novo reported improvements in their extra movements and overall satisfaction with deutetrabenazine QD.

Authors/Disclosures
Kejsi Begaj, PharmD PRESENTER	No disclosure on file
Rakesh Jain, MD	Dr. Jain has received personal compensation in the range of $1,000,000+ for serving as a Consultant for AbbVie, Acadia, Adamas, Alfasigma, Alkermes, Almatica, Axsome, Biogen, Boehringer Ingleheim, Corium, Cingulate Therapeutics, Eisai, Evidera, Impel, Janssen, Lilly, Lundbeck, Merck, Neos Therapeutics, Neurocrine Biosciences, Osmotica, Otsuka, Pamlab, Pfizer, Sage Therapeutics, Shire, Sumitomo, Sunovion, Supernus, Takeda, Teva, Transcend Therapeutics and Viatris. Dr. Jain has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Usona. Dr. Jain has received personal compensation in the range of $1,000,000+ for serving on a Speakers Bureau for AbbVie, Alkermes, Almatica, Axsome, Corium, Eisai, Indivior, Intra-Cellular Therapies, Ironshore Pharmaceuticals, Janssen, Lilly, Lundbeck, Merck, Neos Therapeutics, Neurocrine, Otsuka, Pamlab, Pfizer, Shire, Sunovion, Takeda, Teva, Tris Pharmaceuticals and Viatris.
Martijn Konings (Teva Pharmaceutical Inc.)	Martijn Konings has received personal compensation for serving as an employee of Teva Pharmaceuticals. Martijn Konings has stock in Teva Pharmaceuticals.
Maurice Driessen (Teva)	No disclosure on file
Sameer Kotak, BS Pharm, MS, MBA	Mr. Kotak has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Teva.
Pooja Gandhi	Pooja Gandhi has received personal compensation for serving as an employee of Teva Pharmaceuticals. Pooja Gandhi has stock in Teva Pharmaceuticals.

��ɫ��

��ɫ��